Profile Image

Professor Xu Dong Zhang

Professor

School of Biomedical Sciences and Pharmacy

Driving Skin Cancer Research

Navigating the cellular highways of skin cancer is a complex journey and Professor Xu Dong Zhang is a driving force in mapping the pathways of melanoma that have, until recently, remained a mystery.

One of the world's most eminent researchers in skin cancer, University of Newcastle's Professor Zhang discovered a molecular pathway that has the potential to save the lives of people diagnosed with melanoma, the most dangerous form of skin cancer.

More than 130,000 melanomas are diagnosed worldwide with 1,500 Australians dying from the disease each year. Australia holds the unfortunate title of the highest incidence of melanoma in the world.

Professor Xu Dong Zhang in a research lab

The Road to a Cure

In 2013, Professor Zhang was the Chief Investigator for an international collaboration that unearthed a molecular pathway that plays an important role in the development of melanoma and its resistance to treatment.

"There are tens of thousands of genes in every cell so discovering the important ones is an art. It takes a lot of work and lot of faith but Xu Dong has a knack for picking the right molecules," said fellow University of Newcastle cancer researcher, Dr Rick Thorne.

Cancer is caused by the uncontrolled division of cells, which can invade adjacent tissue or travel through the body in a process called metastasis. In the majority of cases, cancer researchers look for deregulated genes that drive cell division.

Using a combination of molecular and cellular biology and biochemistry techniques, Professor Zhang's recent discovery captured worldwide attention because it showed that a lack of molecule called PIB5PA in the cells – rather than a surplus or mutations – could be a major cause of melanoma.

"This finding changes not only the way we view melanoma, but could also have significance for other kinds of cancer," Professor Zhang said.

The PIB5PA molecule helps keep the cell normal and regulated and this loss activates a chain reaction called the PI3K/Akt pathway which occurs in up to 70 per cent of melanomas.

Professor Zhang and his team found they could inhibit the growth of melanoma cells, and even shrink established melanomas by restoring PIB5PA levels.

"The molecule was commonly absent in melanoma cells. By restoring its expression, it actually made the melanoma cells behave more normally and this happened straight away," Professor Zhang said.

"Currently there are no effective therapies for metastatic melanoma - except to cut it out. If the cancer travels beyond the original site the patient's chance of surviving is not good. The PIB5PA discovery provides a potential new treatment."

Professor Zhang said his team is now exploring targeted approaches to blocking the Akt pathway and hope they will have a new melanoma treatment within the next few years.

"We'll also be exploring whether PIB5PA can serve as a biomarker for likely progression of some melanomas," he said.

Driver of change

Head of the Melanoma Research Laboratory at the University of Newcastle and Calvary Mater Newcastle Hospital, Professor Zhang has spent the past 15 years searching for a cure for metastatic melanoma.

The PIB5PA breakthrough builds on Professor Zhang's other ground-breaking discoveries in the field that have led to his reputation as a global leader in melanoma research. These breakthroughs include a significant contribution to understanding the resistance of melanoma cells to apoptosis, a form of cell death that is the main mechanism used by therapeutic drugs to kill cancer cells.

Professor Zhang also pioneered two areas of melanoma research, overcoming resistance of melanoma cells to apoptosis induced by TNF-related apoptosis-inducing ligand, otherwise known as TRAIL (a soluble factor that can be produced by immune cells and selectively kill cancer cells without affecting normal tissues) and examining the response of melanoma cells to a cellular stress condition called endoplasmic reticulum (ER) stress.

"Skin cancer is complex, it's difficult and it's a huge challenge, but every step we take is one step further towards realising a molecularly designed personalised therapy," Professor Zhang said.

"There are so many pathways, proteins and molecules within the cells. If you interfere with a few pathways you may temporarily stop melanoma growth. However, within a very short period the patient will relapse and the tumour will return. So we need to find more pathways and more proteins and develop more therapeutic approaches."

"Adding to this is the fact that no melanoma cells vary wildly. Even within a tumour, they may be different from one another."

"It's a race against time trying to blocks the pathways. It's like navigating the LA Freeway. We need to learn as much as we can about the different routes and shortcuts cancer can take so we can learn where we need to place the stop signs for cancer and what that flow-on effect will be."

In the driver's seat

Originally a cancer surgeon in his homeland of the Shanxi region in China, Professor Zhang was fascinated by the complexity of cancer biology when he chose to switch his scalpel for study books in 1995 to pursue a career as a researcher at the University of Newcastle.

"I worked as a surgeon for ten years in China before I came to Australia. I know how difficult it is to treat a cancer patient and because I understand what is really needed by a patient, my research has a strong translational base," Professor Zhang said.  

"The more you know about cancer biology, the more you feel how big the challenge is we have to face. It's a huge mountain and climbing that is what drives me."

Sharing the road

The Co-Director of the Priority Research Centre (PRC) for Cancer at the University of Newcastle and Deputy Director of the Cancer Program of the Hunter Medical Research Institute (HMRI), Professor Zhang said the key to their success in translational research was its collaborations with leading research institutions and universities.

Professor Zhang is leading a number of comparative studies on the biological characteristics of skin cancer cells between Chinese populations and Australian populations.

"In some melanomas in Caucasian populations like Australia, they often have a BRAF gene mutation. However, melanomas in Asian populations don't commonly have a BRAF mutation," Professor Zhang said.

"This is important research because Asian and Australian populations might respond differently to treatments due to biological differences," he said. 

Professor Zhang has established fruitful collaborations with several Top 20 Universities in China, including the University of Science and Technology of China, the Sichuan University, and the Sun Yat-sen University.  He also holds honorary professorships at a number of other institutions in China, including the Anhui Medical University, the Fourth Military Medical University, and the Shanxi Cancer Hospital and Shanxi Cancer Institute. He is an honorary director of the Cellular and Molecular Biology Laboratory at the Shanxi Cancer Hospital and Shanxi Cancer Institute.

His global reputation is reflected by his H Factor of 31, his invited presentations in many international and national conferences, and his appointment on the editorial board for a number of scientific journals.

"The University of Newcastle's collaboration with leading universities in China has enabled us to open up new ideas and share resources, such as tumour tissues. We have co-authored at least 30 publications in high quality journals together, with more to come."

Professor Zhang credits the integrated medical academic hub with the Melanoma Unit of the Calvary Mater Newcastle Hospital and the University's close association with the Melanoma Institute Australia as also vital.

"Through our links with the Melanoma Institute of Australia the research team has full access to the largest repository of melanoma-related bio-samples with linked follow-up data in the world.

From here, Professor Zhang and his team will be researching what regulates the sensitivity of melanoma cells to cell death induced by targeted therapy. They will also be exploring why the tumour suppressor p53 does not function to suppress melanoma and whether there is any relationship between obesity and melanoma development, progression and resistance to treatment.

As Professor Zhang says, "we'll keep exploring until one of these pathways leads us down the road of stopping melanoma in its tracks."

Meet other UON global leaders

Professor Xu Dong Zhang

Driving Skin Cancer Research

Navigating the cellular highways of skin cancer is a complex journey and Professor Xu Dong Zhang is a driving force in mapping the pathways of melanoma that have, until recently, remained a mystery.One of the world's most eminent researchers in…

Read more

Career Summary

Biography

For more than 15 years, Dr Xu Dong Zhang has focused on translational melanoma research with an overall aim to overcome resistance of metastatic melanoma to treatment. He is currently a Professor heading the Melanoma Research Laboratory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer. Professor Zhang has published more than 80 manuscripts in his research career. The H Factor (Index) of his publications is currently 31. In addition, He has presented my work in a large number of international and national conferences and institutional seminars, with many attendances as an invited speaker. As a chief investigator, He has attracted a large sum of funding for his research. In the past 3 years since, he was awarded an NHMRC Senior Research Fellowship (2011), and successfully renewed, for the third consecutive time, a Cancer Institute NSW (CINSW) Fellowship (2011) that is now awarded in the form of a top-up to the NHMRC Fellowship. He is a chief investigator of a translational melanoma research program grant awarded in 2011 by CINSW, and, as Chief investigator A, he has received 2 NHMRC project grants and 4 Cancer Council NSW project grants since 2009. In addition, He is a co-chief investigator of another NHMRC project grant and a chief investigator of a number of competitive grants from other funding bodies. Professor Zhang’s research has drawn considerable attention in the cancer research community worldwide and his contribution to melanoma research is highly regarded nationally and internationally. He regularly review manuscripts for high impact journals including Cancer Research and Oncogene, and assess grant applications for international and national funding bodies, such as Medical Research Council UK and NHMRC. He was a Grant Review Panel (GRP) member of NHMRC in 2011 and a a panel member of Cancer Australia in 2013. His research has also drawn extensive attention from the general public, with the highlight being 8 interviews by media including the ABC in the past 3 years. His research excellence has enabled me to establish productive collaborations with other researchers, both within academia and commercial organizations. In addition, I provide regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of highly ranked universities and institutes in China. He has proven himself to be highly competent in supervision of research high degree students and junior researchers. Since he received my first conjoint appointment in 2005 from the University of Newcastle, two PhD students have completed their studies in excellent fashion under my supervision. During the past 3 years, two postdoctoral researchers have successfully obtained NHMRC Postdoctoral Training Fellowship under his supervision. At the current time, he is the principal supervisor of 5 PhD candidates, and a co-supervisor of another two. Professor Zhang is a Co-Director of the Priority Research Centre (PRC) for Cancer of the Faulty of Health, and a Deputy Director of the Cancer Program of Hunter Medical Research Institute. He is also a member of various scientific and administering committees, including the HMRI Research Council, the Research Council of Hunter Translational Cancer Research Unit, and the Analytical and Biomolecular Research Facility Advisory Group of University of Newcastle.

Research Expertise
Melanoma is the most serious form of skin cancer that is often referred to as Australia's national cancer as Australia has the highest incidence of melanoma in the world. However, there is currently no curative treatment once the disease spreads beyond the original site. To address this major Australian health problem, Professor Xu Dong Zhang has been working on translational research on melanoma with a focused theme of “overcoming resistance of metastatic melanoma to treatment” for more than 15 years. In particular, he has been recognized nationally and internationally for his significant contribution to understanding resistance mecahnisms of melanoma cells to apoptosis, a form of cell death that is the main mechanism of killing of cancer cells by most anti-cancer therapeutic drugs. Professor Zhang is currently leading the Melanoma Research Laboraotory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer. He pioneered two areas of the the melanoma research field, overcoming resistance of melanoma cells to apoptosis induced by TRAIL (a soluble factor that can be produced by immune cells and selectively kill cancer cells without affecting normal tissues) and examining the response of melanoma cells to a cellular stress condition termed ER stress. While his leading role in these areas has been consolidated in recent years, he has initiated a number of new projects that advance the frontier of melanoma resaerch. These include projects to address the questions “what regulates sensitivity of melanoma cells to apoptosis induced by inhibition of intracellular pro-survival signalling pathways?”, “how do a group of proteins called polyphosphate phosphatase affect melanoma cell malignancy?”, “why does the tumour suppressor p53 not function to suppress melanoma?”, and “is there any relationship between obesity and melanoma development, progression, and resistance to treatment?”. Professor Zhang’s research program is closely allied with the research scheme of the Melanoma Institute Australia (MIA). This not only allows my team to have full access to the largest repository of melanoma-related bio-samples with linked follow-up data in the world, but also fast tracks our scientific exchanges with melanoma researchers nationally and internationally. In addition, my research program is integrated into the research strategy of the Priority Research Center (PRC) for Cancer of UoN and that of the Cancer Research Program (CRP) of the Hunter Medical Research Institute (HMRI). This not only facilitates collaborations between his research team and other local cancer researchers, but also enables him to contribute his research expertise broadly to other cancer research programs in Newcastle.

Teaching Expertise
Tumor biology; Tumor Immunology; Apoptosis; Signaling transduction.

Administrative Expertise
Dr Zhang acts as a team leader of a research group at the oncology and Immunology Unit that is specialized in research on melanoma biology

Collaborations
Professor Zhang’s research excellence has enabled him to establish productive collaborations with other researchers, both within academia and commercial organizations. His research team has successfully completed contract work for the biocompanies, Peplin Biotechnology and Novogene Biotechnology on testing new drugs on melanoma cells. His collaborations with AstraZeneca, Roche, and GlaxoSmithKline (GSK) on testing novel targeted therapeutics are ongoing. His collaborations with Drs Rick Thorne, Nicole Verrills, Nicholas Bowden, Ming Yang, Professors Rodney Scott locally, Professors Richard Kefford and Richard Scolyer and Dr Helen Rizos at the University of Sydney, Drs Tao Liu and Belamy Cheung at the University of New South Wales, and Dr Jiezhong Chen at the University of Wollongong are also continuing. Professor Zhang provides regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of universities and institutes in China. He has been an honorary professor of Anhui Medical University since 2003, and received another honorary professorship from the Fourth Military Medical University in 2010. He was honored with a third professorship in China by Shanxi Cancer Hospital/Shanxi Cancer Institute in 2012. He was also appointed as an honorary director of the Cellular and Molecular Biology Laboratory of the same hospital/institute. Aside from the Chinese universites and institues where Professor Zhang is an honorary professor, He has also established collaborations with researchers from other universities in China, including the Sun Yat-sen University in Guangzhou (Professors Xiao Shi Zhang and Xiao Feng Zhu), the Sichuan University in Chengdu (Dr Yu Fang Wang), and the University of Science and Technology of China in Hefei (Professor Main Wu). All these universities are among top-20 universities in China according to 2011 ranking (the Sun Yat-sen University is ranked 10; the Sichuan University, 12; and the University of Science and Technology of China, 18). These collaborations have proven to be productive and mutually beneficial as demonstrated by collaborative publications and conference presentations.


Qualifications

  • PhD, University of Sydney
  • Bachelor of Medicine, Shanxi Medical University PR China

Keywords

  • Carcinogenesis
  • Cell Death
  • Oncology
  • Signal Transduction

Languages

  • Mandarin (Fluent)

Fields of Research

CodeDescriptionPercentage
060199Biochemistry and Cell Biology not elsewhere classified25
111299Oncology and Carcinogenesis not elsewhere classified75

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
4/07/2014 - 31/01/2016ProfessorUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

DatesTitleOrganisation / Department
1/01/2012 - 31/12/2012Membership - ERA 2012 Cluster Advisory Group (CAG)the ERA 2012 Cluster Advisory Group of University of Newcastle
Australia
1/01/2012 - Membership - Analytical and Biomolecular Research Facility (ABRF) Advisory Groupthe Analytical and Biomolecular Research Facility (ABRF) Advisory Group of University of Newcastle
Australia
1/06/2011 - 1/06/2014FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2011 - Editorial Board - the Chinese Journal of Stem Cellsthe Chinese Journal of Stem Cells
Australia
1/01/2011 - Editorial Board - The Scientific World JournalThe Scientific World Journal
Australia
1/01/2011 - Membership - Grant Review PanelNHMRC Grant Review Panel
Australia
1/01/2011 - Membership - Executive Committee of Hunter Translational Cancer Research Unit (TCRU)Executive Committee of Hunter Translational Cancer Research Unit (TCRU)
Australia
1/01/2010 - Editorial Board - World Journal of Gastrointestinal OncologyWorld Journal of Gastrointestinal Oncology
Australia
1/07/2005 - Fellow - Cancer Institute NSWCancer Institute NSW
Australia
1/01/2005 - Membership - the Hunter Medical Research Institute (HMRI) Cancer Research Program (CRP) Steering Committeethe Hunter Medical Research Institute (HMRI) Cancer Research Program (CRP) Steering Committee
Australia
1/01/2002 - 1/02/2011Senior Hospital ScientistCalvary Newcastle Mater Hospital
Australia
1/01/2001 - Membership - American Association for Cancer Research (AACR) American Association for Cancer Research (AACR)
United States

Awards

Research Award

YearAward
2004Young Researcher of the Year
Hunter Medical Research Institute (HMRI)

Invitations

Speaker

YearTitle / Rationale
2012Induction of apoptosis: the key for successful treatment of melanoma by mutant BRAF inhibitors?
Organisation: The BIT Science’ 4rd PEPCON Conference Description: To present my research
2010Adaptation to ER stress as a driver of increased expression of Mcl-1 with melanoma progression.
Organisation: 7th Annual International Melanoma Congress Description: To present my research.
2009Up-regulation of Mcl-1 by the Unfolded Protein Response is Critical for Survival of Melanoma Cells upon ER stress.
Organisation: 7th World Congress on Melanoma Description: To present my work
2008Up-regulation of Mcl-1 by the Unfolded Protein Response is Critical for Survival of Melanoma Cells upon ER stress.
Organisation: XXth IPCC & Vth IMRC Description: To present my work
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (5 outputs)

YearCitationAltmetricsLink
2012Lai FS, Jin L, Gallagher S, Mijatov B, Zhang XD, Hersey P, 'Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors', Advances in Pharmacology, Academic Press, Maryland Heights, MO 27-43 (2012) [B1]
CitationsScopus - 10
2012Hersey P, Zhang XD, 'Targeting apoptotic pathways in melanoma', Targeted Therapeutics in Melanoma, Humana Press, New York 125-153 (2012) [B1]
2008Hersey P, Zhang XD, Mhaidat N, 'Overcoming resistance to apoptosis in cancer therapy', Programmed Cell Death in Cancer Progression and Therapy, Springer, Berlin 105-126 (2008) [B1]
DOI10.1007/978-1-4020-6554-5
2006Hersey P, Zhang XD, Mhaidat N, 'Overcoming Resistance to Apoptosis in Cancer Therapy', Programmed Cell Death in Cancer Progression and Therapy, Springer, Berlin, Germany 105-126 (2006) [B1]
CitationsScopus - 9Web of Science - 8
2005Hersey P, Zhang SY, Zhang XD, 'Regulation of trail receptor expression in human melanoma', Death Receptors in Cancer Therapy, Humana Press, New York 175-187 (2005) [B1]
Show 2 more chapters

Journal article (115 outputs)

YearCitationAltmetricsLink
2015Luan Q, Jin L, Jiang CC, Tay KH, Lai F, Liu XY, et al., 'RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy.', Autophagy, 0 (2015)
DOI10.1080/15548627.2015.1049800Author URL
2015Tay KH, Liu X, Chi M, Jin L, Jiang CC, Guo ST, et al., 'Involvement of vacuolar H+-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720', Pigment Cell and Melanoma Research, 28 171-183 (2015)

Targeting the sphingosine 1-phosphate (S1P)/S1P receptor (S1PR) signalling axis is emerging as a promising strategy in the treatment of cancer. However, the effect of such an approach on survival of human melanoma cells remains less understood. Here, we show that the sphingosine analogue FTY720 that functionally antagonises S1PRs kills human melanoma cells through a mechanism involving the vacuolar H+-ATPase activity. Moreover, we demonstrate that FTY720-triggered cell death is characterized by features of necrosis and is not dependent on receptor-interacting protein kinase 1 or lysosome cathepsins, nor was it associated with the activation of protein phosphatase 2A. Instead, it is mediated by increased production of reactive oxygen species and is antagonized by activation of autophagy. Collectively, these results suggest that FTY720 and its analogues are promising candidates for further development as new therapeutic agents in the treatment of melanoma.

DOI10.1111/pcmr.12326
2015Liu XY, Lai F, Yan XG, Jiang CC, Guo ST, Wang CY, et al., 'RIP1 Kinase Is an Oncogenic Driver in Melanoma.', Cancer Res, 75 1736-1748 (2015)
DOI10.1158/0008-5472.CAN-14-2199Author URL
2015Meng XX, Yao M, Zhang XD, Xu HX, Dong Q, 'ER stress-induced autophagy in melanoma.', Clin Exp Pharmacol Physiol, (2015)
DOI10.1111/1440-1681.12436Author URL
2015Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J, et al., 'Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.', Oncotarget, 6 10473-10486 (2015)
Author URL
Co-authorsMarjorie Walker, Hubert Hondermarck, John Attia
2014Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, et al., 'Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.', J Natl Cancer Inst, 106 (2014) [C1]
DOI10.1093/jnci/dju113Author URL
CitationsScopus - 2Web of Science - 1
2014Liu YL, Lai F, Wilmott JS, Yan XG, Liu XY, Luan Q, et al., 'Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells', Oncotarget, 5 11237-11251 (2014) [C1]

Reduction in the expression of the anti-survival BH3-only proteins PUMA and Bim is associated with the pathogenesis of melanoma. However, we have found that the expression of the other BH3-only protein Noxa is commonly upregulated in melanoma cells, and that this is driven by oncogenic activation of MEK/ERK. Immunohistochemistry studies showed that Noxa was expressed at higher levels in melanomas than nevi. Moreover, the expression of Noxa was increased in metastatic compared to primary melanomas, and in thick primaries compared to thin primaries. Inhibition of oncogenic BRAFV600E or MEK downregulated Noxa, whereas activation of MEK/ERK caused its upregulation. In addition, introduction of BRAFV600E increased Noxa expression in melanocytes. Upregulation of Noxa was due to a transcriptional increase mediated by cAMP responsive element binding protein, activation of which was also increased by MEK/ERK signaling in melanoma cells. Significantly, Noxa appeared necessary for constitutive activation of autophagy, albeit at low levels, by MEK/ERK in melanoma cells. Furthermore, it was required for autophagy activation that delayed apoptosis in melanoma cells undergoing nutrient deprivation. These results reveal that oncogenic activation of MEK/ERK drives Noxa expression to promote autophagy, and suggest that Noxa has an indirect anti-apoptosis role in melanoma cells under nutrient starvation conditions.

2014Gong J, Fang L, Liu R, Wang Y, Xing J, Chen Y, et al., 'UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells', EUROPEAN JOURNAL OF IMMUNOLOGY, 44 3758-3767 (2014) [C1]
DOI10.1002/eji.201444574Author URL
2014Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, et al., 'Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress', Journal of Investigative Dermatology, 134 488-497 (2014)
DOI10.1038/jid.2013.325
CitationsScopus - 5
2014Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, et al., 'Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress', Journal of Investigative Dermatology, 134 488-497 (2014) [C1]

Cancer cells commonly undergo chronic endoplasmic reticulum (ER) stress, to which the cells have to adapt for survival and proliferation. We report here that in melanoma cells intrinsic activation of the ER stress response/unfolded protein response (UPR) is, at least in part, caused by increased outputs of protein synthesis driven by oncogenic activation of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) and promotes proliferation and protects against apoptosis induced by acute ER stress. Inhibition of oncogenic BRAF V600E or MEK-attenuated activation of inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) signaling of the UPR in melanoma cells. This was associated with decreased phosphorylation of eukaryotic initiation factor 4E (eIF4E) and nascent protein synthesis and was recapitulated by knockdown of eIF4E. In line with this, introduction of BRAF V600E into melanocytes led to increases in eIF4E phosphorylation and protein production and triggered activation of the UPR. Similar to knockdown of glucose-regulated protein 78 (GRP78), inhibition of XBP1 decelerated melanoma cell proliferation and enhanced apoptosis induced by the pharmacological ER stress inducers tunicamycin and thapasigargin. Collectively, these results reveal that potentiation of adaptation to chronic ER stress is another mechanism by which oncogenic activation of the MEK/ERK pathway promotes the pathogenesis of melanoma. © 2014 The Society for Investigative Dermatology.

DOI10.1038/jid.2013.325
CitationsScopus - 9Web of Science - 5
2014Wu P, Cheng YW, Wang JY, Zhang XD, Zhang LJ, 'Inhibition of MEK sensitizes gastric cancer cells to TRAIL-induced apoptosis', Neoplasma, 61 136-143 (2014) [C1]

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which has long been believed to be highly selective in inducing apoptosis in cancer cells, has turned out to be a molecule that induces a far more diverse range of effects. The aim of this study was to investigate whether or not ERK1/2 pathway is involved in antitumor effects of TRAIL on gastric cancer cells. In addition to activate the extrinsic and intrinsic apoptotic pathway, TRAIL also triggered the activation of ERK1/2. Inhibition of ERK1/2 signaling by MEK inhibitor U0126 promoted cell death via increased activation of caspases, drop in mitochondrial membrane potential and downregulation of XIAP, cIAP2 and Mcl-1. These results indicate that TRAIL-induced rapid activation of ERK1/2 may be a survival mechanism to struggle against TRAIL assault at the early stage, and inhibition of ERK1/2 signaling can sensitize gastric cancer cells to TRAIL-induced apoptosis.

DOI10.4149/neo_2014_019
CitationsScopus - 1
2014Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF, 'Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone', Human Pathology, 45 1664-1673 (2014)
DOI10.1016/j.humpath.2014.04.002
CitationsScopus - 2
2014Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF, 'Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone', Human Pathology, 45 1664-1673 (2014) [C1]

Although diffuse large B-cell lymphoma (DLBCL) encompasses a biologically and clinically diverse set of diseases, increasing evidence has pointed to an important role of microRNAs (miRs) in the pathogenesis of DLBCL. We report here that low expression of miR-146b-5p and miR-320d is associated with poor prognosis of DLBCL patients treated with the standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen and that this is related to the inhibitory effect of these miRs on DLBCL cell proliferation. Analysis of a retrospective cohort of 106 primary nodal DLBCL samples from patients who were treated with CHOP showed that, when the median survival period (40.8 months) was used as the cutoff point, miR-146b-5p and miR-320d were expressed at lower levels in DLBCLs with poor prognosis. Indeed, whereas low expression of miR-146b-5p was correlated with reduced progression-free survival, low expression of miR-320d was associated with decreases in both progression-free survival and overall survival. Moreover, miR-146b-5p and miR-320d were expressed at significantly lower levels in DLBCLs with the MYC t(8;14) translocation. Functional studies demonstrated that overexpression of miR-146b-5p or miR-320d inhibited DLBCL cell proliferation, wheareas knockdown of miR-146b-5p or miR-320d promoted proliferation of DLBCL cells. Taken together, these results suggest that low expression of miR-146b-5p and miR-320d may be predictive of compromised responses of a subset of DLBCL patients to treatment with the CHOP regimen and that restoration of these miRs may be useful to improve the therapeutic efficacy of CHOP. © 2014 Elsevier Inc.

DOI10.1016/j.humpath.2014.04.002
CitationsScopus - 4Web of Science - 3
2014Yang F, Xu N, Li D, Guan L, He Y, Zhang Y, et al., 'A Feedback Loop between RUNX2 and the E3 Ligase SMURF1 in Regulation of Differentiation of Human Dental Pulp Stem Cells', JOURNAL OF ENDODONTICS, 40 1579-1586 (2014) [C1]
DOI10.1016/j.joen.2014.04.010Author URL
2014Tay KH, Luan Q, Croft A, Jiang CC, Jin L, Zhang XD, Tseng H-Y, 'Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress', CELLULAR SIGNALLING, 26 287-294 (2014) [C1]
DOI10.1016/j.cellsig.2013.11.008Author URL
CitationsScopus - 4Web of Science - 5
2014Chi M, Chen J, Ye Y, Tseng H-Y, Lai F, Tay KH, et al., 'Adipocytes Contribute to Resistance of Human Melanoma Cells to Chemotherapy and Targeted Therapy', CURRENT MEDICINAL CHEMISTRY, 21 1255-1267 (2014) [C1]
Author URL
CitationsScopus - 3Web of Science - 3
2014Becker TM, Boyd SC, Mijatov B, Gowrishankar K, Snoyman S, Pupo GM, et al., 'Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor', ONCOGENE, 33 1158-1166 (2014) [C1]
DOI10.1038/onc.2013.45Author URL
CitationsScopus - 4Web of Science - 2
2014Dong L, Jin L, Tseng H-Y, Wang CY, Wilmott JS, Yosufi B, et al., 'Oncogenic suppression of PHLPP1 in human melanoma', ONCOGENE, 33 4756-4766 (2014) [C1]
DOI10.1038/onc.2013.420Author URL
CitationsScopus - 3Web of Science - 1
2014Jiang CC, Croft A, Tseng H-Y, Guo ST, Jin L, Hersey P, Zhang XD, 'Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma', Oncogene, 33 2577-2588 (2014)
DOI10.1038/onc.2013.237
CitationsScopus - 3
2014Jiang CC, Croft A, Tseng H-Y, Guo ST, Jin L, Hersey P, Zhang XD, 'Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma', Oncogene, 33 2577-2588 (2014) [C1]

Increased global protein synthesis and selective translation of mRNAs encoding proteins contributing to malignancy is common in cancer cells. This is often associated with elevated expression of eukaryotic translation initiation factor 4 (eIF4E), the rate-limiting factor of cap-dependent translation initiation. We report here that in human melanoma downregulation of miR-768-3p as a result of activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has an important role in the upregulation of eIF4E and enhancement in protein synthesis. Melanoma cells displayed increased nascent protein production and elevated eIF4E expression, which was associated with the downregulation of miR-768-3p that was predicted to target the 3'-untranslated region of the eIF4E mRNA. Overexpression of miR-768-3p led to the downregulation of the endogenous eIF4E protein, reduction in nascent protein synthesis and inhibition of cell survival and proliferation. These effects were efficiently reversed when eIF4E was co-overexpressed in melanoma cells. On the other hand, introduction of anti-miR-768-3p into melanocytes upregulated endogenous eIF4E protein expression and increased global protein synthesis. Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAF V600E melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAF V600E or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis. This inhibition was partially blocked in cells cointroduced with anti-miR-768-3p. Significantly, miR-768-3p was similarly downregulated, which was inversely associated with the expression levels of eIF4E in fresh melanoma isolates. Taken together, these results identify downregulation of miR-768-3p and subsequent upregulation of eIF4E as an important mechanism in addition to phosphorylation of eIF4E responsible for MEK/ERK-mediated enhancement of protein synthesis in melanoma. © 2014 Macmillan Publishers Limited.

DOI10.1038/onc.2013.237
CitationsScopus - 6Web of Science - 4
2014Ye Y, Li Q, Ge Y-M, Zhang X-D, Zhang L-J, 'The effects of PIB5PA on migration and invasion of human melanoma cells', Tumor, 34 487-493 (2014) [C1]

Objective: To investigate the effects of phosphatidylinositol 4, 5-bisphosphate 5-phosphatase A (PIB5PA) on the migration and invasion of human melanoma Mel-FH cells. Methods: Eukaryotic expression recombinant vector pF-5xUAS-SV40-PIB5PA which carried a 4-hydroxytamoxifen (4-OHT)-inducible lentiviral expression system was constructed and infected into melanoma Mel-FH cells. Mel-FH.PIB5PA cells were successfully obtained via dual antibiotic selection of puromycin and hygromycin B. The optimum concentration and acting time of 4-OHT on the expression of PIB5PA of Mel-FH.PIB5PA cells were detected by Western blotting. The migration and invasion of Mel-FH.PIB5PA cells were determined by wound healing and Transwell chamber assay, respectively. The expression levels of phospho-protein kinase B (p-AKT), phospho-focal adhesion kinase (p-FAK), matrix metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and TIMP-2 were measured by Western blotting. Results: The addition of 10 nmol/L 4-OHT for 16 h readily induced PIB5PA overexpression in Mel-FH.PIB5PA cells. The exogenous expression of PIB5PA significantly inhibited migration and invasion of Mel-FH.PIB5PA cells as compared with Mel-FH.PIB5PA cells without treatment of 4-OHT (P < 0.05), and reduced the expression levels of p-AKT, p-FAK, MMP-2, MMP-9, TIMP-1, TIMP-2, MMP-2/ TIMP-2 and MMP-9/TIMP-1 proteins (all P < 0.05). Conclusion: Over-expression of PIB5PA can inhibit the abilities of migration and invasion of human melanoma Mel-FH cells in vitro , which may be associated with inactivity of AKT and FAK, and down-regulation of the relative expression levels of MMP-2/TIMP-2 and MMP-9/TIMP-1. Copyright© 2014 by TUMOR.

DOI10.3781/j.issn.1000-7431.2014.06.001
2014Chi M, Ye Y, Zhang XD, Chen J, 'Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway', Drug Design, Development and Therapy, 8 255-262 (2014) [C1]

There is currently no curative treatment for melanoma once the disease spreads beyond the original site. Although activation of the PI3K/Akt pathway resulting from genetic mutations and epigenetic deregulation of its major regulators is known to cause resistance of melanoma to therapeutic agents, including the conventional chemotherapeutic drug dacarbazine and the Food and Drug Administration-approved mutant BRAF inhibitors vemurafenib and dabrafenib, the role of extracellular stimuli of the pathway, such as insulin, in drug resistance of melanoma remains less understood. Objective: To investigate the effect of insulin on the response of melanoma cells to dacarbazine, and in particular, the effect of insulin on the response of melanoma cells carrying the BRAFV600E mutation to mutant BRAF inhibitors. An additional aim was to define the role of the PI3K/Akt pathway in the insulin-triggered drug resistance. Methods: The effect of insulin on cytotoxicity induced by dacarbazine or the mutant BRAF inhibitor PLX4720 was tested by pre-incubation of melanoma cells with insulin. Cytotoxicity was determined by the MTS assay. The role of the PI3K/Akt pathway in the insulin-triggered drug resistance was examined using the PI3K inhibitor LY294002 and the PI3K and mammalian target of rapamycin dual inhibitor BEZ-235. Activation of the PI3K/Akt pathway was monitored by Western blot analysis of phosphorylated levels of Akt. Results: Recombinant insulin attenuated dacarbazine-induced cytotoxicity in both wild-type BRAF and BRAFV600E melanoma cells, whereas it also reduced killing of BRAFV600E melanoma cells by PLX4720. Nevertheless, the protective effect of insulin was abolished by the PI3K and mTOR dual inhibitor BEZ-235 or the PI3K inhibitor LY294002. Conclusion: Insulin attenuates the therapeutic efficacy of dacarbazine and PLX4720 in melanoma cells, which is mediated by activation of the PI3K/Akt pathway and can be overcome by PI3K inhibitors. © 2014 Chi et al.

DOI10.2147/DDDT.S53568
CitationsScopus - 1
2014Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H, Liu Z, 'Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination.', Autophagy, 10 257-268 (2014) [C1]
DOI10.4161/auto.27162Author URL
CitationsScopus - 14Web of Science - 14
2014Oliveira CS, de Bock CE, Molloy TJ, Sadeqzadeh E, Geng XY, Hersey P, et al., 'Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma', BMC Cancer, 14 (2014) [C1]

Background: Macrophage migration inhibitory factor (MIF) is a widely expressed cytokine involved in a variety of cellular processes including cell cycle regulation and the control of proliferation. Overexpression of MIF has been reported in a number of cancer types and it has previously been shown that MIF is upregulated in melanocytic tumours with the highest expression levels occurring in malignant melanoma. However, the clinical significance of high MIF expression in melanoma has not been reported. Methods: MIF expression was depleted in human melanoma cell lines using siRNA-mediated gene knockdown and effects monitored using in vitro assays of proliferation, cell cycle, apoptosis, clonogenicity and Akt signalling. In silico analyses of expression microarray data were used to correlate MIF expression levels in melanoma tumours with overall patient survival using a univariate Cox regression model. Results: Knockdown of MIF significantly decreased proliferation, increased apoptosis and decreased anchorage-independent growth. Effects were associated with reduced numbers of cells entering S phase concomitant with decreased cyclin D1 and CDK4 expression, increased p27 expression and decreased Akt phosphorylation. Analysis of clinical outcome data showed that MIF expression levels in primary melanoma were not associated with outcome (HR = 1.091, p = 0.892) whereas higher levels of MIF in metastatic lesions were significantly associated with faster disease progression (HR = 2.946, p = 0.003 and HR = 4.600, p = 0.004, respectively in two independent studies). Conclusions: Our in vitro analyses show that MIF functions upstream of the PI3K/Akt pathway in human melanoma cell lines. Moreover, depletion of MIF inhibited melanoma proliferation, viability and clonogenic capacity. Clinically, high MIF levels in metastatic melanoma were found to be associated with faster disease recurrence. These findings support the clinical significance of MIF signalling in melanoma and provide a strong rationale for both targeting and monitoring MIF expression in clinical melanoma.

DOI10.1186/1471-2407-14-630
Co-authorsRick Thorne
2014Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, et al., 'TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells', ONCOTARGET, 5 10127-10139 (2014) [C1]
Author URL
2013Wroblewski D, Jiang CC, Croft A, Farrelly ML, Zhang XD, Hersey P, 'OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.', PLoS One, 8 e84073 (2013) [C1]
DOI10.1371/journal.pone.0084073Author URL
CitationsScopus - 4Web of Science - 3
2013Ye Y, Li Q, Hu WL, Tseng H-Y, Jin L, Zhang XD, et al., 'Loss of PI(4,5)P2 5-phosphatase A contributes to resistance of human melanoma cells to RAF/MEK inhibitors', Translational Oncology, 6 470-481 (2013) [C1]

Past studies have shown that the inositol polyphosphate 5-phosphatase, phosphatidylinositol 4,5-bisphosphate 5-phosphatase (PIB5PA), is commonly downregulated or lost in melanomas, which contributes to elevated activation of phosphatidylinositol 3-kinase (PI3K)/Akt in melanoma cells. In this report, we provide evidence that PIB5PA deficiency plays a role in resistance of melanoma cells to RAF/mitogen-activated protein kinase kinase (MEK) inhibitors. Ectopic expression of PIB5PA enhanced apoptosis induced by the RAF inhibitor PLX4720 in BRAFV600E and by the MEK inhibitor U0126 in both BRAFV600E and wild-type BRAF melanoma cells. This was due to inhibition of PI3K/Akt, as co-introduction of an active form of Akt (myr-Akt) abolished the effect of over-expression of PIB5PA on apoptosis induced by PLX4720 or U0126. While overexpression of PIB5PA triggered activation of Bad and down-regulation of Mcl-1, knockdown of Bad or overexpression of Mcl-1 recapitulated, at least in part, the effect of myr-Akt, suggesting that regulation of Bad and Mcl-1 is involved in PIB5PA-mediated sen-sitization of melanoma cells to the inhibitors. The role of PIB5PA deficiency in BRAF inhibitor resistance was confirmed by knockdown of PIB5PA, which led to increased growth of BRAFV600E melanoma cells selected for resistance to PLX4720. Consistent with its role in vitro, overexpression of PIB5PA and the MEK inhibitor selumetinib cooperatively inhibited melanoma tumor growth in a xenograft model. Taken together, these results identify loss of PIB5PA as a novel resistance mechanism of melanoma to RAF/MEK inhibitors and suggest that restoration of PIB5PA may be a useful strategy to improve the therapeutic efficacy of the inhibitors in the treatment of melanoma. © 2013 Neoplasia Press, Inc. All rights reserved.

DOI10.1593/tlo.13277
CitationsScopus - 4Web of Science - 2
2013Wroblewski D, Mijatov B, Mohana-Kumaran N, Lai F, Gallagher SJ, Haass NK, et al., 'The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance', CARCINOGENESIS, 34 237-247 (2013) [C1]
DOI10.1093/carcin/bgs330Author URL
CitationsScopus - 13Web of Science - 12
2013Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, et al., 'MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer', ONCOGENE, 32 1910-1920 (2013) [C1]
DOI10.1038/onc.2012.214Author URL
CitationsScopus - 41Web of Science - 34
Co-authorsRick Thorne
2013Chen J, Chi M, Chen C, Zhang XD, 'Obesity and melanoma: Exploring molecular links', Journal of Cellular Biochemistry, 114 1955-1961 (2013) [C1]
DOI10.1002/jcb.24549Author URL
CitationsScopus - 4Web of Science - 2
2013Li Y, Liu H, Huang YY, Pu LJ, Zhang XD, Jiang CC, Jiang ZW, 'Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 31 1234-1242 (2013) [C1]
DOI10.3892/ijmm.2013.1292Author URL
CitationsScopus - 8Web of Science - 6
2013Chen J, Shao R, Zhang XD, Chen C, 'Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics', International Journal of Nanomedicine, 2013 2677-2688 (2013) [C1]
DOI10.2147/IJN.S45429
CitationsScopus - 12Web of Science - 11
2013Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, et al., 'The histone deacetylase SIRT2 stabilizes Myc oncoproteins', CELL DEATH AND DIFFERENTIATION, 20 503-514 (2013) [C1]
DOI10.1038/cdd.2012.147Author URL
CitationsScopus - 31Web of Science - 28
Co-authorsC Scarlett
2013Sun X-J, Liu H, Zhang P, Zhang X-D, Jiang Z-W, Jiang C-C, 'miR-10b Promotes Migration and Invasion in Nasopharyngeal Carcinoma Cells', ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 14 5533-5537 (2013) [C1]
DOI10.7314/APJCP.2013.14.9.5533Author URL
CitationsScopus - 17Web of Science - 15
2013Carlino MS, Gowrishankar K, Saunders CAB, Pupo GM, Snoyman S, Zhang XD, et al., 'Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma', Molecular Cancer Therapeutics, 12 1332-1342 (2013) [C1]

Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP-ERK kinase (MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic melanoma. The clinical benefit of MAPK inhibitors is restricted by the development of acquired resistance with half of those who benefit having progressed by 6 to 7 months and long-term responders uncommon. There remains no agreed treatment strategy on disease progression in these patients. Without published evidence, fears of accelerated disease progression on inhibitor withdrawal have led to the continuation of drugs beyond formal disease progression. We now show that treatment with MAPK inhibitors beyond disease progression can provide significant clinical benefit, and the withdrawal of these inhibitors led to a marked increase in the rate of disease progression in two patients. We also show that MAPK inhibitors retain partial activity in acquired resistant melanoma by examining drug-resistant clones generated to dabrafenib, trametinib, or the combination of these drugs. All resistant sublines displayed a markedly slower rate of proliferation when exposed to MAPK inhibitors, and this coincided with a reduction in MAPK signaling, decrease in bromodeoxyuridine incorporation, and S-phase inhibition. This cytostatic effect was also associated with diminished levels of cyclin D1 and p-pRb. Two shortterm melanoma cultures generated from resistant tumor biopsies also responded to MAPK inhibition, with comparable inhibitory changes in proliferation and MAPK signaling. These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy. ©2013 AACR.

DOI10.1158/1535-7163.MCT-13-0011
CitationsScopus - 20Web of Science - 18
2013Song L, Liu H, Ma L, Zhang X, Jiang Z, Jiang C, 'Inhibition of autophagy by 3-MA enhances endoplasmic reticulum stress-induced apoptosis in human nasopharyngeal carcinoma cells', ONCOLOGY LETTERS, 6 1031-1038 (2013) [C1]
DOI10.3892/ol.2013.1498Author URL
CitationsScopus - 2Web of Science - 2
2013Chen J, Zhang XD, Jiang Z, 'The Application of Fungal Beta-glucans for the Treatment of Colon Cancer', ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 13 725-730 (2013) [C1]
Author URL
CitationsScopus - 1
2013Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, et al., 'Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma', PLOS ONE, 8 (2013) [C1]
DOI10.1371/journal.pone.0070424Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsRodney Scott, Katie Ashton, Kelly Kiejda, Nikola Bowden
2013Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, et al., 'PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma', NATURE COMMUNICATIONS, 4 (2013) [C1]
DOI10.1038/ncomms2489Author URL
CitationsScopus - 15Web of Science - 15
Co-authorsRick Thorne
2013Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, et al., 'Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3', CELL DEATH & DISEASE, 4 (2013) [C1]
DOI10.1038/cddis.2013.192Author URL
CitationsScopus - 6Web of Science - 7
2013Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, et al., 'AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.', Cell Death and Disease, 4 e914 (2013) [C1]
DOI10.1038/cddis.2013.441
CitationsScopus - 4Web of Science - 6
2012Tseng HY, Chen L, Ye Y, Tay KH, Jiang CC, Guo ST, et al., 'The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells', Carcinogenesis, 33 1871-1881 (2012) [C1]
CitationsScopus - 3Web of Science - 3
2012Xu W-H, Zhang A-M, Ren M-S, Zhang XD, Wang F, Xu X-C, et al., 'Changes of treg-associated molecules on CD4 +CD25 +treg cells in myasthenia gravis and effects of immunosuppressants', Journal of Clinical Immunology, 32 975-983 (2012) [C1]
CitationsScopus - 8Web of Science - 10
2012Lai FS, Jiang CC, Farrelly ML, Zhang XD, Hersey P, 'Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors', Melanoma Research, 22 244-251 (2012) [C1]
CitationsScopus - 10Web of Science - 10
2012Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, et al., 'Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-Mimetic ABT-737', Clinical Cancer Research, 18 783-795 (2012) [C1]
CitationsScopus - 33Web of Science - 31
2012Zhan Z, Li Q, Wu P, Ye Y, Tseng HY, Zhang L, Zhang XD, 'Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1', Autophagy, 8 109-121 (2012) [C1]
CitationsScopus - 15Web of Science - 15
2012Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al., 'Guidelines for the use and interpretation of assays for monitoring autophagy', Autophagy, 8 445-544 (2012) [C1]
CitationsScopus - 937Web of Science - 948
2012Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 e337 (2012) [C1]
CitationsScopus - 15Web of Science - 15
Co-authorsRick Thorne, Nikki Verrills
2011Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al., 'P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation', BMC Cancer, 11 203-219 (2011) [C1]
DOI10.1186/1471-2407-11-203
CitationsScopus - 28Web of Science - 21
Co-authorsNikola Bowden, Rodney Scott, Kelly Kiejda, Bente Talseth-Palmer, Katie Ashton
2011Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD, 'MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720', Clinical Cancer Research, 17 721-730 (2011) [C1]
CitationsScopus - 58Web of Science - 56
Co-authorsRick Thorne
2011Sadeqzadeh E, De Bock CE, Zhang XD, Shipman KL, Scott NM, Song C, et al., 'Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products', Journal of Biological Chemistry, 286 28181-28191 (2011) [C1]
DOI10.1074/jbc.M111.234419
CitationsScopus - 13Web of Science - 12
Co-authorsRick Thorne
2011Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, et al., 'MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma', Proceedings of the National Academy of Sciences, 108 15840-15845 (2011) [C1]
CitationsScopus - 58Web of Science - 58
Co-authorsRick Thorne
2011Wilmott JS, Zhang XD, Hersey P, Scolyer RA, 'The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers', Pathology, 43 657-671 (2011) [C1]
DOI10.1097/PAT.0b013e32834a7358
CitationsScopus - 13Web of Science - 17
2011Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, et al., 'Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress', Oncogene, 30 3716-3726 (2011) [C1]
DOI10.1038/onc.2011.87
CitationsScopus - 28Web of Science - 27
Co-authorsRick Thorne
2010Tseng H-Y, Jiang CC, Croft A, Croft A, Thorne RF, Yang F, et al., 'Contrasting effects of Nutlin-3 on TRAIL - and Docetaxel-induced Apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells', Molecular Cancer Therapeutics, 9 3363-3374 (2010) [C1]
DOI10.1158/1535-7163.MCT-10-0646
Co-authorsRick Thorne
2010Jiang CC, Lai F, Tay KH, Croft A, Rizos H, Becker TM, et al., 'Apoptosis of human melanoma cells induced by inhibition of B-RAF(V600E) involves preferential splicing of bim(S)', Cell Death & Disease, 1 e69 (2010) [C1]
DOI10.1038/cddis.2010.48
CitationsScopus - 50Web of Science - 50
Co-authorsRick Thorne
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Nucleotide excision repair gene expression after cisplatin treatment in melanoma', Cancer Research, 70 7918-7926 (2010) [C1]
CitationsScopus - 8Web of Science - 7
Co-authorsKatie Ashton, Kelly Kiejda, Rodney Scott, Nikola Bowden
2010Thorne RF, Ralston KJ, De Bock CE, Mhaidat NM, Zhang XD, Boyd AW, Burns GF, 'Palmitoylation of CD36/FAT regulates the rate of its post-transcriptional processing in the endoplasmic reticulum', Biochimica et Biophysica Acta - Molecular Cell Research, 1803 1298-1307 (2010) [C1]
DOI10.1016/j.bbamcr.2010.07.002
CitationsScopus - 9Web of Science - 9
Co-authorsRick Thorne
2010Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF, Hersey P, 'Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins', Modern Pathology, 23 45-53 (2010) [C1]
DOI10.1038/modpathol.2009.129
CitationsScopus - 25Web of Science - 24
2010Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E, et al., 'Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIPL from degradation by the E3 ligase itch in human melanoma cells', Cell Death and Differentiation, 17 1354-1367 (2010) [C1]
DOI10.1038/cdd.2010.29
CitationsScopus - 29Web of Science - 26
Co-authorsRick Thorne
2010Mao ZG, Jiang CC, Thorne RF, Hersey P, Zhang XD, 'TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4', Apoptosis, 15 1211-1222 (2010) [C1]
DOI10.1007/s10495-010-0513-9
CitationsScopus - 12Web of Science - 10
Co-authorsRick Thorne
2009Liu H, Jiang CC, Lavis CJ, Croft A, Dong L, Tseng H-Y, et al., '2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2', Molecular Cancer, 8 Article no. 122 (2009) [C1]
DOI10.1186/1476-4598-8-122
CitationsScopus - 31Web of Science - 23
2009Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD, 'Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt', Neoplasia, 11 436-447 (2009) [C1]
DOI10.1593/neo.09208
CitationsScopus - 28Web of Science - 26
Co-authorsRick Thorne
2009Jiang CC, Wroblewski D, Yang F, Hersey P, Zhang XD, 'Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax', Neoplasia, 11 945-955 (2009) [C1]
DOI10.1593/neo.09692
CitationsScopus - 31Web of Science - 27
2009Jiang CC, Mao ZG, Kiejda KA, Hersey P, Zhang XD, 'Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells', Carcinogenesis, 30 197-204 (2009) [C1]
DOI10.1093/carcin/bgn220
CitationsScopus - 43Web of Science - 41
Co-authorsKelly Kiejda
2009Zhang LJ, Chen S, Wu P, Hu CS, Thorne RF, Luo CM, et al., 'Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells', Cancer Letters, 274 40-46 (2009) [C1]
DOI10.1016/j.canlet.2008.08.030
CitationsScopus - 24Web of Science - 22
Co-authorsRick Thorne
2009Zhuang L, Scolyer RA, Lee CS, McCarthy SW, Cooper WA, Zhang XD, et al., 'Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma', Histopathology, 54 462-470 (2009) [C1]
DOI10.1111/j.1365-2559.2009.03242.x
CitationsScopus - 50Web of Science - 40
2009Hersey P, Zhang XD, 'Treatment combinations targeting apoptosis to improve immunotherapy of melanoma', Cancer Immunology, Immunotherapy, 58 1749-1759 (2009) [C1]
DOI10.1007/s00262-009-0732-5
CitationsScopus - 17Web of Science - 15
2009Hersey P, Watts RN, Zhang XD, Hackett J, 'Metabolic approaches to treatment of melanoma', Clinical Cancer Research, 15 6490-6494 (2009) [C1]
DOI10.1158/1078-0432.ccr-09-0251
CitationsScopus - 16Web of Science - 16
2009Zhang X-H, Li SC, Fong K-Y, Thumboo J, 'The Impact of Health Literacy on Health-Related Quality of Life (HRQoL) and utility assessment among patients with rheumatic diseases', Value in Health, 12 S106-S109 (2009) [C1]
DOI10.1111/j.1524-4733.2009.00640.x
CitationsScopus - 12Web of Science - 9
Co-authorsShuchuen Li
2008Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin', Clinical Cancer Research, 14 1659-1668 (2008) [C1]
DOI10.1158/1078-0432.ccr-07-1422
CitationsScopus - 49Web of Science - 44
Co-authorsKelly Kiejda, Rodney Scott
2008Mhaidat NM, Thorne RF, Zhang XD, Hersey P, 'Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma', Apoptosis, 13 1505-1512 (2008) [C1]
DOI10.1007/s10495-008-0276-8
CitationsScopus - 17Web of Science - 16
Co-authorsRick Thorne
2008Hersey P, Zhang XD, 'Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma', Pigment Cell and Melanoma Research, 21 358-367 (2008) [C1]
DOI10.1111/j.1755-148x.2008.00467.x
CitationsScopus - 47Web of Science - 47
2008Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein', Cancer Research, 68 834-842 (2008) [C1]
DOI10.1158/0008-5472.can-07-5056
CitationsScopus - 27Web of Science - 24
Co-authorsKelly Kiejda, Rick Thorne
2008Jiang CC, Lucas K, Kiejda KA, Wade M, Debock CE, Thorne RF, et al., 'Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress', Cancer Research, 68 6708-6717 (2008) [C1]
DOI10.1158/0008-5472.can-08-0349
CitationsScopus - 73Web of Science - 69
Co-authorsRick Thorne, Kelly Kiejda
2008Mhaidat NM, Thorne RF, De Bock CE, Zhang XD, Hersey P, 'Melanoma cell sensitivity to docetaxal-induced apoptosis is determined by class III beta-tubulin levels', FEBS Letters, 582 267-272 (2008) [C1]
DOI10.1016/j.febslet.2007.12.014
CitationsScopus - 9Web of Science - 8
Co-authorsRick Thorne
2008Mhaidat NM, Thorne RF, De Bock CE, Zhang XD, Hersey P, 'Melanoma cell sensitivity to docetaxal-induced apoptosis is determined by class III beta-tubulin levels', FEBS Letters, 582 267-272 (2008) [C1]
DOI10.1016/j.febslet.2007.12.014
Co-authorsRick Thorne
2008Zhu B-K, Wang P, Zhang XD, Jiang CC, Chen LH, Kiejda KA, et al., 'Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells', Anti-Cancer Drugs, 19 189-200 (2008) [C1]
DOI10.1097/CAD.0b013e3282f3138a
CitationsScopus - 20Web of Science - 21
Co-authorsKelly Kiejda
2008Zhang LJ, Hao YZ, Hu CS, Ye Y, Xie QP, Thorne RF, et al., 'Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells', Anti-Cancer Drugs, 19 159-166 (2008) [C1]
DOI10.1097/CAD.0b013e3282f30d05
CitationsScopus - 6Web of Science - 7
Co-authorsRick Thorne
2007Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P, 'Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma', Modern Pathology, 20 416-426 (2007) [C1]
DOI10.1038/modpathol.3800750
CitationsScopus - 89Web of Science - 95
2007Mhaidat NM, Zhang XD, Jiang CC, Hersey P, 'Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway', Clinical Cancer Research, 13 1308-1314 (2007) [C1]
DOI10.1158/1078-0432.ccr-06-2216
CitationsScopus - 43Web of Science - 40
2007Yu FW, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P, 'Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1', Clinical Cancer Research, 13 4934-4942 (2007) [C1]
DOI10.1158/1078-0432.CCR-07-0665
CitationsScopus - 96Web of Science - 106
Co-authorsKelly Kiejda
2007Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P, 'Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2', Molecular Cancer Therapeutics, 6 752-761 (2007) [C1]
DOI10.1158/1535-7163.MCT-06-0564
CitationsScopus - 51Web of Science - 46
Co-authorsKelly Kiejda
2007Mhaidat NM, Thorne RF, Zhang XD, Hersey P, 'Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C', Molecular Cancer Research, 5 1073-1081 (2007) [C1]
DOI10.1158/1541-7786.mcr-07-0059
CitationsScopus - 21Web of Science - 19
Co-authorsRick Thorne
2007Mhaidat NM, Zhang XD, Allen J, Kiejda KA, Scott R, Hersey P, 'Temozolomide induces senescence but not apoptosis in human melanoma cells', British Journal of Cancer, 97 1225-1233 (2007) [C1]
DOI10.1038/sj.bjc.6604017
CitationsScopus - 36Web of Science - 33
Co-authorsRodney Scott, Kelly Kiejda
2007Jiang CC, Li HC, Gillespie S, Kiejda KA, Mhaidat N, Yu FW, et al., 'Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response', Cancer Research, 67 5880-5888 (2007) [C1]
DOI10.1158/0008-5472.CAN-07-0213
CitationsScopus - 61Web of Science - 61
Co-authorsKelly Kiejda, Rick Thorne
2007Jiang CC, Li HC, Gillespie S, Yu FW, Kiejda KA, Zhang XD, Hersey P, 'Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis', Cancer Research, 67 9750-9761 (2007) [C1]
DOI10.1158/0008-5472.CAN-07-2047
CitationsScopus - 78Web of Science - 74
Co-authorsKelly Kiejda
2007Chen LH, Jiang CC, Kiejda KA, Wang YF, Thorne RF, Zhang XD, Hersey P, 'Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response', Carcinogenesis, 28 2328-2336 (2007) [C1]
DOI10.1093/carcin/bgm173
CitationsScopus - 30Web of Science - 24
Co-authorsKelly Kiejda, Rick Thorne
2006Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, et al., 'Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand', Human Pathology, 37 1286-1294 (2006) [C1]
DOI10.1016/j.humpath.2006.04.026
CitationsScopus - 45Web of Science - 45
2006Yu F, Watts RN, Zhang XD, Borrow JM, Hersey P, 'Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells', Anti-Cancer Drugs, 17 1151-1161 (2006) [C1]
DOI10.1097/01.cad.0000231484.17063.9a
CitationsScopus - 26Web of Science - 23
2006Gillespie S, Borrow J, Zhang XD, Hersey P, 'Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells', Apoptosis, 11 2251-2265 (2006) [C1]
DOI10.1007/s10495-006-0283-6
CitationsScopus - 38Web of Science - 41
2006Zhang XD, Wu JJ, Gillespie S, Borrow JM, Hersey P, 'Cross resistance of melanoma to trail-induced apoptosis and chemotherapy', Update on Cancer Therapeutics, 1 435-441 (2006) [C1]
DOI10.1016/j.uct.2006.08.004
2006Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P, 'Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin', Clinical Cancer Research, 12 1355-1364 (2006) [C1]
DOI10.1158/1078-0432.CCR-05-2084
CitationsScopus - 37Web of Science - 39
2005Wu JJ, Zhang XD, Gillespie S, Hersey P, 'Selection for TRAIL resistance results in melanoma cells with high proliferative potential', FEBS Letters, 579 1940-1944 (2005) [C1]
DOI10.1016/j.febslet.2005.02.041
CitationsScopus - 24Web of Science - 19
2005Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, et al., 'Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma', Journal of Clinical Pathology, 58 1163-1169 (2005) [C1]
DOI10.1136/jcp.2005.025957
CitationsScopus - 56Web of Science - 52
2005Allen JD, Zhang XD, Scott CL, Boyle GM, Hersey P, Strasser A, 'Is Apaf-1 expression frequently abrogated in melanoma?', CELL DEATH AND DIFFERENTIATION, 12 680-681 (2005)
DOI10.1038/sj.cdd.4401634Author URL
CitationsWeb of Science - 12
2005Gillespie S, Zhang XD, Hersey P, 'Variable expression of protein kinase CE in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis', Molecular Cancer Therapeutics, 4 668-676 (2005) [C1]
DOI10.1158/1535-7163.MCT-04-0332
CitationsScopus - 33Web of Science - 33
2004Zhang XY, Zhang (Ext) XD, Borrow JM, Nguyen T, Hersey P, 'Translational Control of Tumor Necrosis Factor-related Apoptosis-inducing Ligand Death Receptor Expression in Melanoma Cells', Journal of Biological Chemistry, 279 10606-10614 (2004) [C1]
DOI10.1074/jbc.M308211200
CitationsWeb of Science - 17
2004Zhang (Ext) XD, Gillespie SK, Hersey P, 'Staurosporine induces apoptosis of melanoma by both caspase-dependant and -independant apoptotic pathways', Molecular Cancer Therapeutics, 3 187-197 (2004) [C1]
CitationsScopus - 118Web of Science - 112
2004Zhang (Ext) XD, Gillespie SK, Borrow JM, Hersey P, 'The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells', Molecular Cancer Therapeutics, 3 425-435 (2004) [C1]
CitationsScopus - 110Web of Science - 108
2004Gillespie SK, Zhang XD, Hersey P, 'Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced aopootsis in melanoma cells', Molecular Cancer Therapeutics, 3 1651-1658 (2004) [C1]
CitationsScopus - 28Web of Science - 24
2003Hersey P, Zhang XD, 'Resistance of follicular lymphoma cells to chemotherapy is more than just Bcl-2', CANCER BIOLOGY & THERAPY, 2 541-543 (2003)
Author URL
CitationsWeb of Science - 2
2003Xu DZ, Gillespie SK, Borrow JM, Hersey P, 'The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis', Biochemical Pharmacology, 66 1537-1545 (2003) [C1]
DOI10.1016/S0006-2952(03)00509-4
CitationsWeb of Science - 70
2003Hersey P, Zhang (Ext) XD, 'Overcoming resistance of cancer cells to apoptosis', Journal of Cellular Physiology, 196 9-18 (2003) [C1]
DOI10.1002/jcp.10256
CitationsScopus - 87Web of Science - 84
2003Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P, 'Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria', ONCOGENE, 22 2869-2881 (2003)
DOI10.1038/sj.onc.1206427Author URL
CitationsWeb of Science - 98
2001Zhang X, Zhang X, Gray C, Nguyen T, Hersey P, 'Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria', Cancer Research, 61 7339-7348 (2001) [C1]
CitationsWeb of Science - 177
2001Franco A, Zhang X, Van Berkel E, Sanders J, Zhang X, Thomas W, et al., 'The role of NF-kB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells', The Journal of Immunology, 166 5337-5345 (2001) [C1]
CitationsWeb of Science - 104
2001Nguyen T, Zhang X, Hersey P, 'Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis', Clinical Cancer Research, 7 966s-973s (2001) [C1]
CitationsScopus - 76Web of Science - 58
2001Hersey P, Zhang X, 'How melanoma cells evade trail-induced apoptosis', Nature Reviews Cancer, 1 142-150 (2001) [C1]
CitationsWeb of Science - 148
2000Zhang X, Nguyen T, Thomas W, Sanders J, Hersey P, 'Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types', FEBS Letters, 482 193-199 (2000) [C1]
CitationsScopus - 170Web of Science - 172
2000Zhang X, Franco A, Nguyen T, Gray C, Hersey P, 'Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells', The Journal of Immunology, 164 No 8 3961-3970 (2000) [C1]
CitationsWeb of Science - 158
2000Thomas W, Zhang X, Franco A, Nguyen T, Hersey P, 'TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Melanoma is Associated with Changes in Mitochondrial Membrane Potential and Perinuclear Clustering of Mitochondria', The Journal of Immunology, 165 No 10 5612-5620 (2000) [C1]
CitationsWeb of Science - 80
2000Nguyen T, Thomas W, Zhang X, Gray C, Hersey P, 'Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma', Forum: Trends in Experimental and Clinical Medicine, 10 243-252 (2000) [C3]
CitationsScopus - 16
1999Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P, 'Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma', CANCER RESEARCH, 59 2747-2753 (1999)
Author URL
CitationsWeb of Science - 322
1999Zhang XD, Hersey P, 'Expression of catenins and p120(cas) in melanocytic nevi and cutaneous melanoma: Deficient alpha-catenin expression is associated with melanoma progression', PATHOLOGY, 31 239-246 (1999)
Author URL
CitationsWeb of Science - 16
Show 112 more journal articles

Conference (64 outputs)

YearCitationAltmetricsLink
2014Jin L, Liu XY, Lai F, Yan XG, Jiang C, Guo ST, et al., 'Receptor-Interacting Protein Kinase 1 Functions as an oncogenic regulator in human melanoma.', Hunter Cancer Research Symposium, Newcastle, Australia (2014) [E3]
2014Tseng HY, Luan Q, Jin L, Jiang C, Tay KH, Lai F, et al., 'Receptor-Interacting Protein Kinase 1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy', Hunter Cancer Research Symposium, Newcastle, Australia (2014) [E3]
2014Jiang C, Chi MN, Guo ST, Wilmott JS, Guo XG, Yan XG, et al., 'MicroRNA regulation of inositol polyphosphate 4-phosphatase II to modulate melanocytic cell proliferation through PI3K/SGK3 signaling', Hunter Cancer Research Symposium, Newcastle, Australia (2014) [E3]
2014Chi MN, Chen J, Ye Y, Tseng HY, Lai F, Tay KH, et al., 'Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting, Newcastle, Australia (2014) [E3]
2014Wang CY, Jiang C, Chi MN, Croft A, Guo ST, Zhang XD, 'Reactivation of Akt and ERK protects against HSP90 inhibitors in human colon cancer cells.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting., Newcastle, Australia (2014) [E3]
2014Lai F, Guo ST, Jin L, Jiang C, Wang CY, Croft A, et al., 'Cotargeting histone deacetylases and oncogenic BRAF synergistically kills melanoma cells by necrosis independently of RIPK1 and RIPK3.', The Australian Society for Medical Research (ASMR) Satellite Scientific Meeting., Newcastle, Australia (2014) [E3]
2014Wang CY, Jiang CC, Guo ST, Croft A, Jin L, Tseng H-Y, et al., 'TARGETING MEK/ERK AND PI3K/AKT TO OVERCOME RESISTANCE OF HUMAN COLON CANCER TO HSP90 INHIBITORS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2014Croft A, Tay KH, Philipsz S, Jiang CC, Lai F, Tseng H-Y, et al., 'ONCOGENIC ACTIVATION OF MEK/ERK PRIMES MELANOMA CELLS FOR ADAPTATION TO ENDOPLASMIC RETICULUM STRESS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2014Guo ST, Chi MN, Yang RH, Guo XY, Wang CY, Zan LQ, et al., 'INOSITOL POLYPHOSPHATE 4-PHOSPHATASE II PROMOTES PI3K SIGNALING AND FUNCTIONS AS AN ONCOGENIC REGULATOR IN HUMAN COLON CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsRick Thorne, Stephen Ackland, Rodney Scott
2014Wang JY, Wang CY, Jiang CC, Tseng H-Y, Guo ST, Jin L, Zhang XD, 'REGULATION OF SENSITIVITY OF HUMAN MELANOMA CELLS TO KILLING BY THE HUMAN MUT T HOMOLOG1 INHIBITOR', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
2013Guo ST, Lal F, Jiang CC, Wang CY, Farrelly M, Tseng H-Y, et al., 'Co-targeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cell by caspase-independent cell death.', CANCER RESEARCH, Washington, DC (2013) [E3]
DOI10.1158/1538-7445.AM2013-2028Author URL
2013Cheung BB, Sutton SK, Tan O, Koach J, Liu B, Liu T, et al., 'TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma', CANCER RESEARCH, Washington, DC (2013) [E3]
DOI10.1158/1538-7445.AM2013-3876Author URL
2013Jin L, Li D, Wang CY, Tseng H-Y, Wilmott JS, Yosufi B, et al., 'PHLPP1 Deactivates Akt and has a Tumour Suppressive Role in Human Melanoma', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2013) [E3]
Author URL
2013Tseng H-Y, Lai F, Jin L, Jiang CC, Kefford R, Long G, et al., 'Inhibition of Oncogenic BRAF Triggers Immunogenic Necrosis of Human Melanoma Cells', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2013) [E3]
Author URL
2012Hersey P, Wroblewski D, Mijatov B, Zhang XD, Haass N, 'Effect of the BH3 mimetic ABT-737 on human melanoma cells to apoptosis induced by selective BRAF inhibitors.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2012) [E3]
Author URL
2011Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Downstream effects of reduction in nucleotide excision repair in response to cisplatin treatment in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
Co-authorsNikola Bowden, Rodney Scott, Kelly Kiejda, Katie Ashton
2011Ye Y, Jin L, Wilmott J, Hu WL, Thorne RF, Dong L, et al., 'Phosphatidylinositol 4,5-Bisphosphate 5-Phosphatase A regulates PI3K/Akt signaling in human melanoma cells', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
Co-authorsRick Thorne
2011Hersey P, Wroblewski DJR, Lai FS, Jiang CC, Zhang XD, 'Targeting anti-apoptotic mechanisms for reversal of resistance to BRAF inhibitors in melanoma', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
2011Sadeqzadeh E, Hersey P, Zhang XD, Debock C, Boyd A, Burns GF, Thorne RF, 'Aberrant processing of Fat1 Cadherin in human cancer', Clinical Biochemistry, Mashhad, Iran (2011) [E3]
Co-authorsRick Thorne
2010Dong L, Jiang CC, Thorne RF, Yang F, Liu H, De Bock CE, et al., 'Transcriptional up-regulation of Mcl-1 by ETS1 down-stream of XBP-1 in melanoma cells upon ER stress', Pigment Cell & Melanoma Research, Sydney, Australia (2010) [E3]
Co-authorsRick Thorne
2010Chen LH, Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, et al., 'Cystatin B inhibition of TRAIL-induced apoptosis is associated with protection of FLIPLfrom degradation by the E3 ligase itch human melanoma cells', Pigment Cell & Melanoma Research, Sydney, Australia (2010) [E3]
DOI10.1038/cdd.2010.29
Co-authorsRick Thorne
2010Yang XM, Chen LH, Jiang CC, De Bock CE, Thorne RF, Hersey P, Zhang XD, '40p53 is up-regulated and plays a role in antagonizing p53-mediated apoptosis in human melanoma', Pigment Cell & Melanoma Research, Sydney, Australia (2010) [E3]
Co-authorsRick Thorne
2010Zhang XD, Jiang CC, Lai F, Croft A, Tay KH, Thorne RF, et al., 'Apoptotic response of mutant B-RAF human melanoma cells to a B-RAF inhibitor involves increased splicing production of BimS', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsRick Thorne
2010Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
DOI10.1158/0008-5472.CAN-10-0161
Co-authorsKelly Kiejda, Katie Ashton, Rodney Scott, Nikola Bowden
2010Salum De Oliveira C, Yan XG, Hersey P, Zhang XD, Thorne RF, 'The role of MIF signaling in melanoma progression', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsRick Thorne
2010Jiang CC, Zhuang LQ, Dong L, Thorne RF, Lavis CJ, Hersey P, Zhang XD, 'Adaptation to ER stress as a driver of increased expression of Mcl-1 with melanoma progression', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsRick Thorne
2010Ashton KA, Bowden NA, Kairupan CF, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Base excision repair and gene expression profiling in malignant melanoma', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsKatie Ashton, Rodney Scott, Nikola Bowden, Kelly Kiejda
2010Ashton KA, Bowden NA, Vilain RE, Kairupan CF, Kiejda KA, Zhang XD, et al., 'Genetic variation of the base excision repair gene, MUTYH, and melanoma development', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
Co-authorsNikola Bowden, Katie Ashton, Kelly Kiejda
2010Bowden NA, Ashton KA, Kiejda KA, Vilain RE, Braye SG, Kairupan CF, et al., 'Nucleotide excision repair gene expression in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
DOI10.1158/0008-5472.CAN-10-0161
Co-authorsNikola Bowden, Katie Ashton, Kelly Kiejda
2010Zhang XD, Jiang CC, Zhuang LQ, Hersey P, 'Adaptation to ER stress as a mechanism of resistance of melanoma to treatment', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Becker TM, Philips S, Mijatov B, Pupo GM, Gowrishankar K, Kefford RF, et al., 'Analysis of oncogenic BRAF mediated Mcl-1 regulation in melanocytes', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Croft A, Lai F, Jiang CC, Zhang XD, Hersey P, 'Active XBP1 levels may predict resistance of B-Raf V600E melanoma cell lines to PLX4720', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Jiang CC, Lai FS, Hersey P, Zhang XD, 'Preferential splicing of BimS plays a predominant role in induction of apoptosis in human melanoma cells', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Lai F, Jiang CC, Hersey P, Zhang XD, 'Long-term exposure to the B-RAFV600E inhibitor PLX4720 results in melanoma cells with increased activation of ERK1/2 and high proliferation potential', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Wroblewski DJR, Zhang XD, Hersey P, 'Induction of endoplasmic reticulum stress and upregulation of Bcl-2 family proteins in melanoma cells by the BH3 mimetics obatoclax and ABT-737', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Wilmott J, Scolyer RA, Zhang XD, Hersey P, 'The role of p53, microRNA-149*, GSK-3 and MCL-1 in melanoma', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Watts RN, Hackett JA, Zhang XD, Hersey P, 'Proton pump inhibitor omeprazole and NAC complex induces apoptosis in melanoma cell lines', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2010Tseng HY, Jiang CC, Croft A, Tay KH, Yang F, Liu H, et al., 'Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis in human melanoma cells', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
DOI10.1158/1535-7163.MCT-10-0646
CitationsScopus - 17Web of Science - 17
Co-authorsRick Thorne
2010Tay KH, Jiang CC, Tseng HY, Hersey P, Zhang XD, 'Rapid negative feedback regulation of CHOP contributes to resistance of melanoma cells to ER stress-induced apoptosis', Melanoma 2010 Congress. Oral and Poster Abstracts, Sydney, NSW (2010) [E3]
2009Kiejda KA, Scurr LL, Wade MA, Jiang CC, Weir AJW, Bowden NA, et al., 'Cisplatin induces apoptosis independently of Noxa or PUMA in human melanoma cells', 21st Lorne Cancer Conference, Lorne, VIC (2009) [E3]
Co-authorsRodney Scott, Kelly Kiejda, Nikola Bowden
2009Zhang XD, Jiang CC, Kiejda KA, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', 7th World Congress on Melanoma, 5th Congress of the European Association of Dermato-Oncology (EADO): Final Program, Vienna, Austria (2009) [E3]
Co-authorsKelly Kiejda
2009Kairupan CF, Bowden NA, Ashton KA, Zhang XD, Hersey P, Scott R, 'Gene expression profiling in malignant melanoma', AMATA 2009, Katoomba, NSW (2009) [E3]
Co-authorsRodney Scott, Katie Ashton, Nikola Bowden
2008Bowden NA, Ashton KA, Kiejda KA, Zhang XD, Hersey P, Scott R, 'Altered nucleotide excision repair gene expression after cisplatin treatment in melanoma', Proceedings of the Australian Health and Medical Research Congress 2008, Brisbane, QLD (2008) [E3]
Co-authorsKelly Kiejda, Nikola Bowden, Rodney Scott, Katie Ashton
2008Zhang XD, Jiang CC, Avery-Kiejda KA, Lucas K, Wade M, Allen J, Hersey P, 'Up-regulation of Mcl-1 by the unfolded protein response is critical for survival of melanoma cells upon ER stress', PIGMENT CELL & MELANOMA RESEARCH (2008) [E3]
Author URL
Co-authorsKelly Kiejda
2008Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Cooper WA, Zhang XD, et al., 'The glucose-regulated stress protein GRP78 is upregulated during progression of melanoma', PIGMENT CELL & MELANOMA RESEARCH (2008) [E3]
Author URL
2008Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'The P53 splice variants, P53B and 40P53, are expressed in human melanoma cells and can differnetially regulate the transcription of P53 target genes in response to cisplatin', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
Co-authorsRodney Scott, Kelly Kiejda
2008Jiang CC, Wade MA, Kiejda KA, Wang Y, Zhang XD, Hersey P, 'Up-regulation of MCL-1 is critical for survival of human melanoma cells upon ER stress', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
Co-authorsKelly Kiejda
2008Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK/ERK pathway potentiates adaptation of human melanoma to endoplasmic reticulum stress', 20th Lorne Cancer Conference, Lorne, VIC (2008) [E3]
Co-authorsKelly Kiejda
2007Hersey P, Zhang XD, Jiang CC, Chen LH, 'Endoplasmic stress (ER) in melanoma cells', Archives of Dermatological Research, Barcelona, Spain (2007) [E3]
2007Jiang CC, Chen IH, Kiejda KA, Gillespie SK, Hersey P, Zhang XD, 'The unfolded protein response induced by tunicamycin or thapsigargin sensitizes human melanoma cells to trail-induced apoptosis by selective up-regulaton of trail-R2 on te cell surface', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]
Co-authorsKelly Kiejda
2007Kiejda KA, Zhang XD, Hersey P, 'The P53 splice variant, P53B, is widely expressed in human melanoma', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]
Co-authorsKelly Kiejda
2007Zhang XD, Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Hersey P, 'Regulation of the BCL-2 family members BIM, PUMA and MCL-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', 19th Lorne Cancer Conference, Lorne, VIC (2007) [E3]
Co-authorsKelly Kiejda
2007Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'MEK/ERK-mediated regulation of the Bcl-2 family members Mcl-1, PUMA, and Bim contributes to survival of human melanoma cells', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
Co-authorsRodney Scott, Kelly Kiejda
2007Kiejda KA, Zhang XD, Adams LJ, Scott R, Vojtesek B, Lane DP, Hersey P, 'Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by cisplatin', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
Co-authorsRodney Scott, Kelly Kiejda
2007Zhang XD, Jiang CC, Wang YF, Kiejda KA, Hersey P, 'The MEK-ERK pathway potentiates adaptation of melanoma to endoplasmic reticulum stress', 4th Garvan Signalling Symposium. Conference Proceedings, Sydney, NSW (2007) [E3]
Co-authorsKelly Kiejda
2007Jiang CC, Wang YF, Kiejda KA, Gillespie SK, Zhang XD, Hersey P, 'Regulation of the Bcl-2 family members Bim, PUMA and Mcl-1 by MEK/ERK signaling plays a critical role in survival of melanoma cells', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
Co-authorsKelly Kiejda
2006Hersey P, Zhang XD, Gillespie S, 'Hurdles to overcome in treatment of melanoma by TRAIL', JOURNAL OF IMMUNOTHERAPY, Los Angeles, CA (2006)
Author URL
2006Kiejda KA, Zhang XD, Hersey P, 'p53 variants in human melanoma', 13th Annual p53 Workshop. Program & Abstracts, New York (2006) [E3]
Co-authorsKelly Kiejda
2006Jiang CC, Wang YF, Kiejda KA, Zhang XD, Hersey P, 'CD133, A potential marker for cancer stem cells in melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]
Co-authorsKelly Kiejda
2006Kiejda KA, Zhang XD, Hersey P, 'Expression of P53 variants in human melanoma', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]
Co-authorsKelly Kiejda
2006Wang YF, Jiang CC, Kiejda KA, Zhang XD, Hersey P, 'Suppression of the BH3-only proteins BUM and PUMA by MEK/ERK signaling plays a crucial role in maintaining survival of melanoma cells', HMRI Conference on Translational Cancer Research. Molecular Mechanisms and Implications for Treatment, Newcastle, NSW (2006) [E3]
Co-authorsKelly Kiejda
2004Hersey P, Zhang XD, Zhang XY, Borrow J, Gillespie S, 'Sensitising human melanoma cells to apoptosis induced by the immune system', JOURNAL OF INVESTIGATIVE DERMATOLOGY, Sydney, AUSTRALIA (2004)
Author URL
2004Hersey P, Zhang XD, Wu JJ, Gillespie S, 'Cross resistance of melanoma cells to apoptosis induced by trail and chemotherapy', JOURNAL OF IMMUNOTHERAPY, San Francisco, CA (2004)
DOI10.1097/00002371-200411000-00166Author URL
2003Zhang XD, Gillespie SK, Hersey P, 'The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces apoptosis by triggering changes in mitochondrial membrane permeability of melanoma cells.', CLINICAL CANCER RESEARCH, BOSTON, MASSACHUSETTS (2003)
Author URL
Show 61 more conferences
Edit

Grants and Funding

Summary

Number of grants42
Total funding$6,707,864

Click on a grant title below to expand the full details for that specific grant.


20153 grants / $1,217,325

Significance of soluble PD-L1 in melanoma patients$542,975

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Xu Dong Zhang, Dr Helen Rizos, Dr Matteo Carlino, Doctor Patrick McElduff
SchemeProject Grant
RoleLead
Funding Start2015
Funding Finish2015
GNoG1400138
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Elevated INPP4B as a biomarker and therapeutic target in colorectal cancer$343,987

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Professor Rodney Scott
SchemeResearch Grant
RoleLead
Funding Start2015
Funding Finish2015
GNoG1400352
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

RIP1 as a novel therapeutic target in melanoma $330,363

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang
SchemeResearch Grant
RoleLead
Funding Start2015
Funding Finish2015
GNoG1400339
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20144 grants / $345,114

High Throughput Image Capture Platform for Translational Cancer Research$282,614

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamConjoint Professor Stephen Ackland, Professor Rodney Scott, Professor John Forbes, Professor Xu Dong Zhang, Professor Marjorie Walker, Professor Hubert Hondermarck, Doctor Craig Gedye, Doctor Rick Thorne, Mr Loui Rassam, Doctor Stephen Braye
SchemeResearch Equipment Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1400626
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Circulating microRNAs and RNAs as biomarkers of response and toxicity to chemoradiotherapy for oesophageal cancer$22,500

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Xu Dong Zhang, Conjoint Professor Stephen Ackland
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1401397
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

RIPK1 as a novel therapeutic target in melanoma$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Lei Jin, Professor Xu Dong Zhang
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301258
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Overcoming resistance of KRAS mutant colon cancer to treatment by targeting heat shock protein 90$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Chen Chen Jiang, Professor Xu Dong Zhang
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1401417
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20135 grants / $788,096

Functional consequences of epigenetic repression of PIB5PA in melanoma$359,250

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Dr Helen Rizos, Doctor Rick Thorne, Doctor Chen Chen Jiang
SchemeResearch Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1200386
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,250

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang
SchemeResearch Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1200388
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

2013 International Visitor - Guo$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Xu Dong Zhang, Professor Sutang Guo
SchemeDVCR International Visitor Support
RoleLead
Funding Start2013
Funding Finish2013
GNoG1301154
Type Of FundingInternal
CategoryINTE
UONY

20126 grants / $860,668

Targeting Histone Deacetylases to Overcome Resistance of BRAFV600E Melanoma Cells to Apoptosis$346,974

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Xu Dong Zhang, Conjoint Professor Peter Hersey, Dr Tao Liu, Doctor Chen Chen Jiang, Doctor Rick Thorne
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1100133
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
SchemeProject Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200555
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
SchemeEquipment Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1100983
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

The Role of Phosphatidylinositol 4, 5-Bisphosphate 5-Phosphatase A (PIB5PA) in Regulation of PI3K/Akt Signalling in Melanoma$24,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Xu Dong Zhang, Doctor Chen Chen Jiang
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1101121
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

A p53-Mediated Pro-Survival Signaling Pathway in Human Melanoma Progression and Resistance to Treatment$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Xu Dong Zhang, Doctor Rick Thorne, Doctor Chen Chen Jiang
SchemeNear Miss Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200672
Type Of FundingInternal
CategoryINTE
UONY

20115 grants / $1,103,388

Overcoming resistance of human metastatic melanoma to treatment$570,640

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Xu Dong Zhang
SchemeResearch Fellowships
RoleLead
Funding Start2011
Funding Finish2011
GNoG1000048
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Targeting pro-survival mechanisms to sensitize human melanoma to immunotherapy$359,250

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Doctor Ming Yang
SchemeResearch Program
RoleLead
Funding Start2011
Funding Finish2011
GNoG1000379
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Overcoming Resistance of Metastatic Melanoma to Treatment: 53 regulation of Mcl-1 via a microRNA-Mediated Pathway in Melanoma progression and Resistance to Chemotherapy$123,498

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor Xu Dong Zhang
SchemeCareer Development Fellowship
RoleLead
Funding Start2011
Funding Finish2011
GNoG1000815
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Regulation of BimS splicing in response of human melanoma cells to inhibition of BRAFVV600E$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Chen Chen Jiang, Professor Xu Dong Zhang
SchemeProject Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1000988
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Targeting Pro-Survival Mechanisms to Sensitize Human Melanoma to Immunotherapy$25,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Xu Dong Zhang, Doctor Ming Yang
SchemeNear Miss Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001046
Type Of FundingInternal
CategoryINTE
UONY

20104 grants / $270,905

Transcriptional regulation of the expression of Mcl-1 in melanoma cell under ER stress$144,300

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamConjoint Professor Peter Hersey, Professor Xu Dong Zhang, Doctor Li Dong
SchemeTraining (Postdoctoral) Fellowships - Australia-China Exchange Fellowships
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0190308
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Melanoma Institute Australia Translational Research Program$58,405

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor Graham Mann, Professor John Thompson, Professor Rick Kefford, Professor Richard Scolyer, Professor Scott Menzies, Associate Professor Andrew Spillane, Conjoint Professor Peter Hersey, Dr Helen Rizos, Professor Xu Dong Zhang, Professor Richard Christopherson
SchemeTranslational Program Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG1200975
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Targeting Pro-Survival Mechanisms to Sensitize Human Melanoma to Immunotherapy$48,200

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor Xu Dong Zhang
SchemeResearch Innovation Grants
RoleLead
Funding Start2010
Funding Finish2010
GNoG0190555
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

The role of micro-RNA-149 in Regulation of Mcl-1 in Human Melanoma under stress$20,000

Funding body: Hunter Children`s Research Foundation

Funding bodyHunter Children`s Research Foundation
Project TeamDoctor Chen Chen Jiang, Professor Xu Dong Zhang
SchemeResearch Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0900189
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20094 grants / $868,250

Targeting adaptive mechanisms to endoplasmic reticulum stress in melanoma$491,250

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Rick Thorne
SchemeProject Grant
RoleLead
Funding Start2009
Funding Finish2009
GNoG0188902
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$272,000

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Conjoint Professor Peter Hersey, Doctor Kelly Kiejda
SchemeResearch Grant
RoleLead
Funding Start2009
Funding Finish2009
GNoG0188913
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Targeting p53 isoforms, delta-40p53 and p53-beta, to promote chemo-sensitivity in human melanoma$75,000

Funding body: Cancer Australia

Funding bodyCancer Australia
Project TeamDoctor Kelly Kiejda, Professor Xu Dong Zhang, Conjoint Professor Peter Hersey
SchemePriority-driven Collaborative Cancer Research Scheme
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0188914
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

FACSAria$30,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Rick Thorne, Doctor Severine Roselli, Professor Xu Dong Zhang, Dr Charles De Bock, Conjoint Professor Peter Hersey, Professor Gordon Burns
SchemeEquipment Grant
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0189846
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20081 grants / $23,225

Colibri high-performance LED illumination system for fluorescence live cell microscopy$23,225

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Rick Thorne, Dr Charles De Bock, Professor Xu Dong Zhang, Doctor Lisa Lincz, Professor Gordon Burns, Conjoint Professor Peter Hersey, Professor Dirk Van Helden, Conjoint Professor Keith Jones, Professor Roger Smith
SchemeEquipment Grant
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0188545
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20074 grants / $95,000

Characterization of p53 isoforms in human melanoma: do they play a role in chemoresistance?$75,000

Funding body: Cure Cancer Australia Foundation

Funding bodyCure Cancer Australia Foundation
Project Team
SchemeProject Grant
RoleLead
Funding Start2007
Funding Finish2007
GNo
Type Of FundingExternal
CategoryEXTE
UONY

The role of p53 Isoforms in chemoresistances of human melanoma$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Xu Dong Zhang, Doctor Kelly Kiejda
SchemeProject Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187239
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

molecular predictors of risk, progression and treatment response in melanoma$0

Funding body: National Health & Medical Research Council

Funding bodyNational Health & Medical Research Council
Project Team
SchemeProgram Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNo
Type Of FundingExternal
CategoryEXTE
UONY

The role of p53 isoforms in chemoresistance of human melanoma. $0

Funding body: Newcastle Mater Misericordiae Hospital

Funding bodyNewcastle Mater Misericordiae Hospital
Project Team
SchemeSmall Grant
RoleLead
Funding Start2007
Funding Finish2007
GNo
Type Of FundingInternal
CategoryINTE
UONY

20061 grants / $621,143

20054 grants / $497,750

Overcoming resistance of human melanoma to chemotherapy$492,750

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamConjoint Professor Peter Hersey, Professor Xu Dong Zhang, Dr John Allen
SchemeProject Grant
RoleInvestigator
Funding Start2005
Funding Finish2005
GNoG0183933
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

PULSE Young Medical Researcher of the Year Award$5,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Xu Dong Zhang
SchemePULSE Early Career Researcher of the Year Award
RoleLead
Funding Start2005
Funding Finish2005
GNoG0184902
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Overcoming Resistance of Melanoma to Chemotherapy$0

Funding body: National Health & Medical Research Council

Funding bodyNational Health & Medical Research Council
Project Team
SchemeProject
RoleLead
Funding Start2005
Funding Finish2007
GNo
Type Of FundingExternal
CategoryEXTE
UONY

Overcoming Resistance of Melanoma to Chemotherapy: Are Melanoma Stem Cells Key Targets? $0

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project Team
SchemeCareer Development and Support Fellowship
RoleLead
Funding Start2005
Funding Finish2007
GNo
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20031 grants / $17,000

Regulation of TNF Apoptosis Inducing Ligand (TRAIL) Receptor Expression in Human Melanoma Cells.$17,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Peter Hersey, Professor Xu Dong Zhang
SchemeResearch Grant
RoleInvestigator
Funding Start2003
Funding Finish2003
GNoG0182640
Type Of FundingContract - Aust Non Government
Category3AFC
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2015To Look at Long Non-Coding RNAs in Melanoma
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2015Novel Signalling Pathways in Food Allergy and Eosinophilic Oesophagitis
Microbiology, Faculty of Health and Medicine
Principal Supervisor
2015Functional Consequences of Up-Regulation of ACTN4 in Melanoma
General Medicine, Faculty of Health and Medicine
Principal Supervisor
2014ProNGF and its Receptors in Pancreatic Cancer and Melanoma
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2014Targeting Human Mut T Homolog1 in Melanoma
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2014INPP4B as a Novel Therapeutic Target in Melanoma and Colorectal Cancer
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2014Functional Consequences of Epigenetic Repression of PIB5PA in Melanoma
Medical Science, Faculty of Health and Medicine
Principal Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2015Inositol Polyphosphate 4-Phosphatese 11 (INPP4B) Promotes PI3K Signalling and Functions as an Oncogenic Regulator in Human Colon Cancer and Melanoma
Surgery, Faculty of Health and Medicine
Principal Supervisor
2014Targeting Adaptive Mechanisms to Endoplasmic Reticulum Stress in Melanoma
Surgery, Faculty of Health and Medicine
Principal Supervisor
2014Regulation of Apoptosis Induced by Targeting the RAF/MEK/ERK Pathway in Human Melanoma
Surgery, Faculty of Health and Medicine
Principal Supervisor
2013The Role of MIF in Melanoma Progression
Medical Science, Faculty of Health and Medicine
Co-Supervisor
2012Sensitising Human Melanoma Cells to TRAIL-induced Apoptosis
Surgery, Faculty of Health and Medicine
Co-Supervisor
2008Regulation of Endoplasmic Reticulum Stress Induced Apoptosis in Human Melanoma
Surgery, Faculty of Health and Medicine
Consultant Supervisor
2007Overcoming Resistance of Human Melanoma to Chemotherapy-Induced Apoptosis
Surgery, Faculty of Health and Medicine
Co-Supervisor
Edit

News

Xu Dong Zhang

$1m for visionary cancer researchers

May 1, 2015

Two of the University of Newcastle's leading researchers have been awarded more than $1m in grants to focus on discovering new methods of curbing and treating cancer.

melanoma research

New ‘linchpin’ in melanoma survival

March 31, 2015

The lethal double-life of a protein known as RIP1 has been exposed by University of Newcastle cancer researcher Professor Xu Dong Zhang, potentially spurring an all-new generation of highly targeted and long-lasting drugs for melanoma.

Cancer Council NSW research grant success

$1 million in Cancer Council NSW project grants

January 12, 2015

Two University of Newcastle (UON) cancer researchers from the School of Biomedical Sciences and Pharmacy in the Faculty of Health and Medicine have been awarded more than $1 million in Cancer Council NSW project grants for 2015.

Professor Xu Dong Zhang

Melanoma research

January 8, 2014

A new protein that mediates the survival and death of melanoma cells has been identified by University of Newcastle cancer researchers, bringing hope for a new treatment method for the disease.

John Forbes

International spotlight on cancer research

October 23, 2013

Four of North America's leading cancer researchers will give keynote presentations at the international Translational Cancer Research Conference in Newcastle from tomorrow until Friday.

Molecule may hold key to melanoma progression

Molecule may hold key to melanoma progression

February 27, 2013

The search for new pathways to treat melanoma has unearthed a molecular target that may play an important activation role in tumour growth, according to University of Newcastle researchers.

Professor Xu Dong Zhang

Position

Professor
Melanoma Research Laboratory
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Contact Details

Emailxu.zhang@newcastle.edu.au
Phone(02) 4921 8906
Mobile0422621827
Fax(02) 4921 7311

Office

RoomLS3-49
BuildingLife Sciences Building
LocationCallaghan
University Drive
Callaghan, NSW 2308
Australia
Edit